Generate Biomedicines’ proprietary platform aims to use generative biology to upend traditional drug development across therapeutic protein modalities. Gevorg Grigoryan, chief technology officer, and Alex Snyder, chief medical officer, sit down with BI analysts Andrew Galler and Sam Fazeli to discuss the general state of AI in drug development and the unique capabilities of the Generate platform in developing novel biologics.

Butterfly Leads the Drive on Semiconductor to Make the Most Out of Ultrasound
43:42

Citizen Health’s Plan to Put an AI Advocate in Every Patient’s Pocket
50:47

Distalmotion’s Approach to Spread Surgical Robots to More
36:38